Beijing Scitop Bio-tech Co Ltd
SZSE:300858
Income Statement
Earnings Waterfall
Beijing Scitop Bio-tech Co Ltd
Revenue
|
286.1m
CNY
|
Cost of Revenue
|
-133.6m
CNY
|
Gross Profit
|
152.5m
CNY
|
Operating Expenses
|
-84.9m
CNY
|
Operating Income
|
67.6m
CNY
|
Other Expenses
|
24.3m
CNY
|
Net Income
|
91.9m
CNY
|
Income Statement
Beijing Scitop Bio-tech Co Ltd
Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||||||||||
Revenue |
308
N/A
|
315
+2%
|
313
-1%
|
334
+7%
|
339
+2%
|
361
+6%
|
366
+2%
|
364
-1%
|
365
+0%
|
370
+1%
|
354
-4%
|
360
+2%
|
369
+2%
|
355
-4%
|
352
-1%
|
322
-9%
|
299
-7%
|
286
-4%
|
|
Gross Profit | |||||||||||||||||||
Cost of Revenue |
(151)
|
(157)
|
(153)
|
(166)
|
(175)
|
(188)
|
(190)
|
(187)
|
(181)
|
(185)
|
(179)
|
(182)
|
(177)
|
(173)
|
(173)
|
(157)
|
(136)
|
(134)
|
|
Gross Profit |
158
N/A
|
158
+0%
|
159
+1%
|
167
+5%
|
164
-2%
|
173
+6%
|
176
+2%
|
177
+0%
|
183
+4%
|
185
+1%
|
175
-5%
|
179
+2%
|
192
+7%
|
182
-5%
|
179
-1%
|
165
-8%
|
163
-1%
|
153
-7%
|
|
Operating Income | |||||||||||||||||||
Operating Expenses |
(51)
|
(44)
|
(50)
|
(51)
|
(53)
|
(61)
|
(71)
|
(79)
|
(89)
|
(76)
|
(69)
|
(61)
|
(77)
|
(75)
|
(80)
|
(83)
|
(92)
|
(85)
|
|
Selling, General & Administrative |
(40)
|
(38)
|
(38)
|
(41)
|
(41)
|
(46)
|
(53)
|
(56)
|
(62)
|
(65)
|
(61)
|
(55)
|
(56)
|
(59)
|
(62)
|
(62)
|
(59)
|
(57)
|
|
Research & Development |
(14)
|
(16)
|
(17)
|
(18)
|
(17)
|
(20)
|
(24)
|
(26)
|
(25)
|
(28)
|
(24)
|
(23)
|
(20)
|
(21)
|
(26)
|
(30)
|
(31)
|
(36)
|
|
Depreciation & Amortization |
(2)
|
(1)
|
(2)
|
0
|
(3)
|
0
|
0
|
0
|
(6)
|
0
|
0
|
0
|
(7)
|
0
|
0
|
0
|
(9)
|
0
|
|
Other Operating Expenses |
6
|
11
|
7
|
8
|
7
|
6
|
5
|
3
|
4
|
18
|
17
|
16
|
7
|
5
|
8
|
8
|
7
|
8
|
|
Operating Income |
107
N/A
|
114
+6%
|
110
-4%
|
117
+6%
|
111
-5%
|
112
+1%
|
105
-6%
|
97
-7%
|
94
-3%
|
110
+17%
|
107
-3%
|
118
+10%
|
115
-2%
|
107
-7%
|
99
-7%
|
82
-17%
|
72
-12%
|
68
-6%
|
|
Pre-Tax Income | |||||||||||||||||||
Interest Income Expense |
1
|
1
|
2
|
3
|
5
|
11
|
14
|
23
|
15
|
18
|
20
|
13
|
13
|
15
|
20
|
25
|
31
|
33
|
|
Non-Reccuring Items |
3
|
0
|
0
|
0
|
1
|
0
|
2
|
2
|
16
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
1
|
|
Total Other Income |
(0)
|
(2)
|
(3)
|
(3)
|
(4)
|
(2)
|
(1)
|
(2)
|
(0)
|
(1)
|
(1)
|
(1)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
|
Pre-Tax Income |
111
N/A
|
113
+2%
|
108
-4%
|
116
+8%
|
113
-2%
|
121
+7%
|
119
-1%
|
121
+1%
|
124
+3%
|
126
+2%
|
125
-1%
|
129
+3%
|
126
-3%
|
121
-4%
|
118
-3%
|
106
-10%
|
102
-3%
|
101
-1%
|
|
Net Income | |||||||||||||||||||
Tax Provision |
(17)
|
(17)
|
(16)
|
(17)
|
(17)
|
(18)
|
(17)
|
(12)
|
(15)
|
(15)
|
(15)
|
(18)
|
(16)
|
(15)
|
(12)
|
(10)
|
(9)
|
(9)
|
|
Income from Continuing Operations |
93
|
96
|
92
|
99
|
97
|
103
|
103
|
109
|
110
|
111
|
110
|
111
|
110
|
106
|
105
|
95
|
93
|
92
|
|
Net Income (Common) |
93
N/A
|
96
+2%
|
92
-4%
|
99
+8%
|
97
-2%
|
103
+7%
|
103
0%
|
109
+6%
|
110
+1%
|
111
+2%
|
110
-1%
|
111
+1%
|
110
-1%
|
106
-3%
|
105
-1%
|
95
-10%
|
93
-2%
|
92
-2%
|
|
EPS (Diluted) |
1.51
N/A
|
1.53
+1%
|
1.47
-4%
|
1.3
-12%
|
1.37
+5%
|
1.24
-9%
|
0.69
-44%
|
0.72
+4%
|
0.49
-32%
|
0.75
+53%
|
0.74
-1%
|
0.5
-32%
|
0.49
-2%
|
0.38
-22%
|
0.41
+8%
|
0.34
-17%
|
0.35
+3%
|
0.35
N/A
|